

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**Form 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of June 2018**

**Commission File Number 001-38079**

---

**UROGEN PHARMA LTD.**

**(Translation of registrant's name into English)**

---

**9 Ha'Ta'asiya Street  
Ra'anana 4365007, Israel  
(Address of Principal Executive Offices)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-For Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

---

**UroGen Pharma Ltd.**

On June 4, 2018, UroGen Pharma Ltd. (the “**Company**”) held an annual meeting of shareholders (the “**Meeting**”). The proxy statement for the Meeting was filed by the Company with the Securities and Exchange Commission as an exhibit to its Report on Form 6-K on April 25, 2018 (File No. 001-38079) and is incorporated herein by reference. All Proposals 1 through 3 brought before the shareholders at the Meeting were approved by the shareholders.

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**UROGEN PHARMA LTD.**

Date: June 6, 2018

By: /s/ Ron Bentsur  
Ron Bentsur  
Chief Executive Officer